ESMO Annual Congress 2022

Liver Cancer Podcast by International Liver Cancer Association (ILCA)

Episode notes

In this podcast, Lorenza Rimassa and Alejandro Forner summarize four abstracts orally presented during the ESMO annual congress held in Paris in September 2022.

Three abstracts report the results of first-line phase 3 trials of immunotherapy for unresectable hepatocellular carcinoma, and one trial reports the results of a phase 1/2 trial of a new FGFR inhibitor for cholangiocarcinoma.

HCC

LEAP-002 trial tested the combination of pembrolizumab and lenvatinib versus lenvatinib single agent and did not meet its primary endpoints. A second combination trial evaluated the combination of camrelizumab and rivoceranib versus sorafenib in a mostly Asian population showing the superiority of the combination compared to sorafenib, with a higher rate of adverse events. RATIONALE-301 assessed single-agent tislelizumab versus sorafenib demons ... 

 ...  Read more